Program
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036C
Also written as “MHB036C” and “MHB036C for Injection”.
Its studies are mostly in Breast Neoplasms, led by Minghui Pharmaceutical.
Drug pageAnti-TROP-2/Topoisomerase Inhibitor ADC MHB036C: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Nov 30, 20223 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceutical | 33 open or running | phase 2since Nov 30, 2022 | Nov 30, 2022 | Apr 2027phase 2 · NCT06373406 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05642949 · 400 planned · Australia
- Apr 15, 2024Phase 2 study in Advanced Solid TumorNCT06373406 · 200 enrolled · China
- Aug 12, 2025Phase 2 study in Advanced Breast CancerNCT07130383 · 210 planned · China
- Oct 16, 2026Primary completion moved from 2025-12 to 2027-04Date moved laterphase 2 · +16 months · NCT06373406
Ahead
- Apr 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06373406
- Aug 2029Primary completion: phase 2 study in Advanced Breast CancerNCT07130383
TargetBeta
TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07130383Advanced Breast Cancer · China | 2 | Recruiting | Aug 2029 | 210 |
| NCT06373406Advanced Solid Tumor · China | 2 | Active, not recruiting | Apr 2027 | 200 |
| NCT05642949Advanced Solid Tumor · Australia | 2 | Not yet recruiting | Dec 31, 2025 | 400 |
How it is read
Names in the registry
- “MHB036C”, 2 entries
- “MHB036C for Injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.